Medicine
Retevmo 160 mg tablet
Retevmo 160 mg tablet is a prescription medicine containing Selpercatinib for oral use, marketed by Eli Lilly, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions between 15°C and 30°C (59°F…
Key facts
- Active ingredient (INN)
- Selpercatinib
- Brand
- Retevmo
- Strength
- 160 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 60 tablets
- Marketing authorisation holder
- Eli Lilly
- Manufacturer
- Eli Lilly
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions between 15°C and 30°C (59°F to 86°F) are permitted.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01EX22 Selpercatinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 April 2024
- Identifiers
- RxCUI 2370164, 2370170, 2370172 +7DailyMed set ID 7fa848ba-a59c-4144-9f52-64d090f4d828NDC 0002-5562Application NDA218160
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 tablet, coated in 1 bottle | 0002-5562-60 | Eli Lilly | 10 April 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Selpercatinib
Clinical summary
Selpercatinib is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. MedsAcross supplies Selpercatinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SelpercatinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RETEVMO prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Retsevmo: European public assessment report (EPAR) · European Medicines Agency
Need Retevmo 160 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.